Evidence map›Paper›PMID 38985403›Full record

ArticleAIDS and behavior2024

Leveraging A Digital Pill System to Understand Prevention-Effective Adherence to Oral Hiv Pre-Exposure Prophylaxis Among Men Who Have Sex with Men with Substance Use.

Peter R Chai, Georgia R Goodman, Yassir Mohamed, Maria J Bustamante, Hannah Albrechta, Jasper S Lee, Tiffany R Glynn, Kel Boland, Joanne Hokayem, Edward W Boyer and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS and behavior, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Peter R ChaiDepartment of Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA. pchai@bwh.harvard.edu.ORCID http://orcid.org/0000-0003-0955-4117
Georgia R GoodmanDepartment of Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.
Yassir MohamedThe Fenway Institute, Fenway Health, Boston, MA, USA.
Maria J BustamanteThe Fenway Institute, Fenway Health, Boston, MA, USA.
Hannah AlbrechtaThe Fenway Institute, Fenway Health, Boston, MA, USA.
Jasper S LeeDepartment of Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.
Tiffany R GlynnDepartment of Emergency Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis St., Boston, MA, 02115, USA.
Kel BolandThe Fenway Institute, Fenway Health, Boston, MA, USA.
Joanne HokayemThe Fenway Institute, Fenway Health, Boston, MA, USA.
Edward W BoyerThe Fenway Institute, Fenway Health, Boston, MA, USA.
Rochelle K RosenThe Centers for Behavioral and Preventive Medicine, The Miriam Hospital, Providence, RI, USA.
Kenneth H MayerThe Fenway Institute, Fenway Health, Boston, MA, USA.
Conall O'CleirighThe Fenway Institute, Fenway Health, Boston, MA, USA.

Funding

The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
PROGRAM FOR AIDS CLINICAL RESEARCH TRAINING (PACRT)T32AI007433 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MARK J SIEDNER · 1992 to 2026
$11.4M
Smart Steps: A context-aware adherence intervention to improve PrEP adherence among men who have sex with men (MSM) with substance use disorderDP2DA056107 · NIDA · BRIGHAM AND WOMEN'S HOSPITAL · PI CHAI, PETER R · 2022 to 2022
$2.7M
Mentoring in Advanced mHealth Technologies and Machine Learning for HIV/Drug Abuse ResearchK24DA037109 · NIDA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI BOYER, EDWARD W · 2014 to 2025
$1.9M
Development of Ingestible Biosensors to Enhance PrEP Adherence in Substance UsersK23DA044874 · NIDA · BRIGHAM AND WOMEN'S HOSPITAL · PI CHAI, PETER R · 2018 to 2022
$1.0M
NIDA National Early Warning System Network (iN3): An Innovative ApproachR56DA038366 · NIDA · WRIGHT STATE UNIVERSITY · PI BOYER, EDWARD W, CARLSON, ROBERT GEOFFREY · 2014 to 2014
$300k
Gilead Sciences ISR-17-10189National Institute of Allergy and Infectious Diseases P30AI060354National Institute of Allergy and Infectious Diseases T32AI007433NIAID NIH HHS P30 AI060354NIAID NIH HHS T32 AI007433NIDA NIH HHS DP2 DA056107NIDA NIH HHS DP2DA056107NIDA NIH HHS K23 DA044874NIDA NIH HHS K23DA044874NIDA NIH HHS K24 DA037109NIDA NIH HHS K24DA037109NIDA NIH HHS R56 DA038366
6 · The paper itself

Abstract

Daily oral pre-exposure prophylaxis (PrEP) is highly effective for HIV prevention, though efficacy depends on adherence. Digital pill systems (DPS) can enable direct, real-time adherence measurement. HIV-negative men who have sex with men (MSM) with substance use (excluding alcohol) utilized a DPS over 90 days and completed weekly surveys reporting sexual activity, condom use, and substance use. Responses indicating (1) any sexual activity and substance use or (2) condomless anal intercourse (CAI) in the prior week were categorized as high risk for HIV acquisition. PrEP adherence data for the 7-day period preceding each response was dichotomized as ≤ 3 and ≥ 4 doses/week, indicating prevention-effective adherence, and compared by HIV risk level. Thirteen MSM were analyzed (median age: 32). Of 113 surveys, 48.7% indicated high HIV risk, with 12.4% reporting CAI alone, 16.8% any sexual activity and substance use, and 19.5% both CAI and substance use. Weekly mean PrEP adherence was 90.3% (6.3 of 7 doses/week), with ≥ 4 doses/week recorded during 92.0% of weeks. The proportion of participants with ≥ 4 recorded doses/week was 88.9% during weeks with CAI alone, 89.5% during weeks with any sexual activity and substance use, 92.0% during weeks with both CAI and substance use, and 92.8% during lower risk weeks. Participants ingested ≥ 4 doses/week during 89.1% of all high-risk weeks and 94.8% of low-risk weeks. Overall, participants maintained high levels of PrEP adherence while engaging in HIV risk behaviors. DPS can be deployed concurrently with data collection tools to assess ingestion patterns during periods of elevated risk.

Indexed as

Anti-HIV AgentsDrug MonitoringHIV InfectionsHomosexuality, MalePre-Exposure ProphylaxisSubstance-Related DisordersAdministration, OralAdultCondomsHumansMaleMiddle AgedRisk-TakingSexual BehaviorSexual PartnersAnti-HIV AgentsDigital pill systemHIV preventionIngestible sensorPrEPPrevention-effective adherence

Identifiers

PMID38985403
PMCPMC11427137

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.